1
|
Rodríguez M, Rebollo-González M, Frutos Díaz-Alejo J, Manso R, Díaz de la Pinta FJ, Torre-Castro J, Rodríguez-Pinilla SM. Mutational profiling of Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders do not resemble nodal peripheral T-cell lymphomas with follicular helper T-cell phenotype. Br J Dermatol 2024:ljae192. [PMID: 38739743 DOI: 10.1093/bjd/ljae192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2024] [Revised: 04/04/2024] [Accepted: 05/10/2024] [Indexed: 05/16/2024]
Abstract
We performed targeted next-generation sequencing (NGS) of 62 selected genes, previously described as being mutated in T-cell lymphomas, in a total of 15 formalin-fixed paraffin-embedded (FFPE) pcSMTLPD patients.
Collapse
Affiliation(s)
- Marta Rodríguez
- Pathology Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain
| | - Marcos Rebollo-González
- Pathology Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain
| | - Jesús Frutos Díaz-Alejo
- Pathology Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain
| | - Rebeca Manso
- Pathology Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain
| | - Francisco Javier Díaz de la Pinta
- Pathology Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain
| | - Juan Torre-Castro
- Dermatology Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain
| | - Socorro María Rodríguez-Pinilla
- Pathology Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), 28040 Madrid, Spain
| |
Collapse
|
2
|
Zazo S, Pérez‐Buira S, Carvajal N, Plaza‐Sánchez J, Manso R, Pérez‐González N, Dominguez C, Prieto‐Potin I, Rubio J, Dómine M, Lozano V, Mohedano P, Carcedo D, Carias R, Rojo F. Actionable mutational profiling in solid tumors using hybrid-capture-based next-generation sequencing in a real-world setting in Spain. Cancer Med 2024; 13:e6827. [PMID: 38213074 PMCID: PMC10905216 DOI: 10.1002/cam4.6827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2023] [Revised: 11/09/2023] [Accepted: 12/08/2023] [Indexed: 01/13/2024] Open
Abstract
OBJECTIVE This study aimed to describe the performance of a next-generation sequencing (NGS) panel for the detection of precise genomic alterations in cancer in Spanish clinical practice. The impact of tumor characteristics was evaluated on informative NGS and actionable mutation rates. MATERIALS AND METHODS A cross-sectional study was conducted at the Fundación Jiménez Díaz University Hospital (May 2021-March 2022) where molecular diagnostic of 537 Formalin-Fixed Paraffin-Embedded (FFPE) tissue samples of diverse solid tumors (lung, colorectal, melanoma, gastrointestinal stromal, among others) was performed using AVENIO Tumor Tissue Targeted Kit. A descriptive analysis of the features of all samples was carried out. Multivariable logistic analysis was conducted to assess the impact of sample characteristics on NGS performance defined by informative results rate (for all tumors and for lung tumors), and on actionable mutations rate (for lung tumors only). RESULTS AVENIO performance rate was 75.2% in all tumor samples and 75.3% in lung cancer samples, and the multivariable analysis showed that surgical specimens are most likely to provide informative results than diagnostic biopsies. Regarding the mutational findings, 727 pathogenic, likely pathogenic, or variant of unknown significance mutations were found in all tumor samples. Single nucleotide variant was the most common genomic alteration, both for all tumor samples (85.3% and 81.9% for all solid tumors and lung samples, respectively). In lung tumors, multivariable analysis showed that it is more likely to find actionable mutations from non-smokers and patients with adenocarcinoma, large cell, or undifferentiated histologies. CONCLUSION This is the largest cohort-level study in Spain to profile the analyses of biopsy samples of different tumors using NGS in routine clinical practice. Our findings showed that the use of NGS routinely provides good rates of informative results and can improve tumor characterization and identify a greater number of actionable mutations.
Collapse
Affiliation(s)
- Sandra Zazo
- Department of PathologyFundación Jiménez Díaz University HospitalMadridSpain
- IIS‐Fundación Jimenez DiazCenter for Biomedical Network Research on Cancer (CIBERONC)MadridSpain
| | - Sandra Pérez‐Buira
- Department of PathologyFundación Jiménez Díaz University HospitalMadridSpain
| | - Nerea Carvajal
- Department of PathologyFundación Jiménez Díaz University HospitalMadridSpain
| | | | - Rebeca Manso
- Department of PathologyFundación Jiménez Díaz University HospitalMadridSpain
| | | | - Carolina Dominguez
- IIS‐Fundación Jimenez DiazCenter for Biomedical Network Research on Cancer (CIBERONC)MadridSpain
| | - Iván Prieto‐Potin
- Department of PathologyFundación Jiménez Díaz University HospitalMadridSpain
| | - Jaime Rubio
- Medical Oncology DepartmentFundación Jiménez Díaz University HospitalMadridSpain
| | - Manuel Dómine
- IIS‐Fundación Jimenez DiazCenter for Biomedical Network Research on Cancer (CIBERONC)MadridSpain
- Medical Oncology DepartmentFundación Jiménez Díaz University HospitalMadridSpain
| | | | | | | | - Rafael Carias
- Department of PathologyFundación Jiménez Díaz University HospitalMadridSpain
| | - Federico Rojo
- Department of PathologyFundación Jiménez Díaz University HospitalMadridSpain
- IIS‐Fundación Jimenez DiazCenter for Biomedical Network Research on Cancer (CIBERONC)MadridSpain
| |
Collapse
|
3
|
Santonja C, Morillo-Giles D, Prieto-Pareja E, Soto-de Ozaeta C, Serrano-del Castillo C, Salgado-Sánchez R, Yi-Shi AWY, Manso R, Rodríguez-Pinilla SM. Leukaemic Presentation of Small-Cell Alk-Positive Anaplastic Large Cell Lymphoma in a Young Woman-Report of a Case with 9-Year Survival. Medicina (Kaunas) 2023; 59:1628. [PMID: 37763746 PMCID: PMC10537167 DOI: 10.3390/medicina59091628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 08/31/2023] [Accepted: 09/06/2023] [Indexed: 09/29/2023]
Abstract
Anaplastic large cell lymphoma (ALCL) with leukaemic presentation (either ab initio or along the course of the disease) has been rarely reported. Irrespective of ALK expression in the neoplastic cells, it features a dismal prognosis. We report a rare case of leukaemic, small cell variant ALK-positive ALCL with 9-year survival in a young woman who was treated upfront with corticosteroids and standard chemotherapy, and review thoroughly the previously published cases. Such an unexpected, good outcome hints at the existence of different clinical subgroups in the leukaemic variant of ALK-positive ALCL.
Collapse
Affiliation(s)
- Carlos Santonja
- Departments of Pathology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (C.S.); (A.-W.-Y.Y.-S.); (S.M.R.-P.)
| | - Daniel Morillo-Giles
- Departments of Haematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (D.M.-G.); (E.P.-P.); (C.S.-d.O.); (C.S.-d.C.); (R.S.-S.)
| | - Elena Prieto-Pareja
- Departments of Haematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (D.M.-G.); (E.P.-P.); (C.S.-d.O.); (C.S.-d.C.); (R.S.-S.)
| | - Carlos Soto-de Ozaeta
- Departments of Haematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (D.M.-G.); (E.P.-P.); (C.S.-d.O.); (C.S.-d.C.); (R.S.-S.)
| | - Cristina Serrano-del Castillo
- Departments of Haematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (D.M.-G.); (E.P.-P.); (C.S.-d.O.); (C.S.-d.C.); (R.S.-S.)
| | - Rocío Salgado-Sánchez
- Departments of Haematology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (D.M.-G.); (E.P.-P.); (C.S.-d.O.); (C.S.-d.C.); (R.S.-S.)
| | - Ana-Wu-Yang Yi-Shi
- Departments of Pathology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (C.S.); (A.-W.-Y.Y.-S.); (S.M.R.-P.)
| | - Rebeca Manso
- Departments of Pathology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (C.S.); (A.-W.-Y.Y.-S.); (S.M.R.-P.)
| | - Socorro María Rodríguez-Pinilla
- Departments of Pathology, Hospital Universitario Fundación Jiménez Díaz, 28040 Madrid, Spain; (C.S.); (A.-W.-Y.Y.-S.); (S.M.R.-P.)
| |
Collapse
|
4
|
Díaz de la Pinta FJ, Moreno MR, Salgado RN, García NC, Santonja C, Buira SP, Piris MA, Requena L, Manso R, Rodríguez-Pinilla SM. Anaplastic Large Cell Lymphomas With The 6p25.3 Rearrangement Are A Heterogeneous Group Of Tumours With A Diverse Molecular Background. Hum Pathol 2023:S0046-8177(23)00102-8. [PMID: 37127078 DOI: 10.1016/j.humpath.2023.04.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 04/21/2023] [Accepted: 04/26/2023] [Indexed: 05/03/2023]
Abstract
ALK-negative anaplastic large cell lymphoma (ALCL) cases with 6p25.3 rearrangement are characterized by peculiar morphological and immunohistochemical features compare to 6p25.3-negative ALK-negative ALCL cases. A subgroup of 6p25.3-positive ALK-negative ALCL cases show the t(6,7)(p25.3;q32.3) rearrangement. Aims: To analyse the differences between 6p25.3-rearranged cases with and without t(6,7)(p25.3;q32.3). Using RNA-sequencing we studied a series of 17 samples showing 6p25.3-rearrangement, identified by FISH, consisting of seven systemic and eight primary cutaneous cases including two examples of secondary skin involvement by systemic ALCL. RNA-sequencing exclusively detected a translocation involving a gene in the 6p25.3 region (either IRF4 or DUSP22) in 7/14 cases (50%). In six of these seven cases the partner proved to be the LINC-PINT region in chromosome 7, while an EXOC2::DUSP22 rearrangement was found in one case. All cases but one were primary cutaneous ALCLs. They all were CD3 positive and BCL2 negative, while most of them expressed p-STAT3. On the contrary, cases without the t(6,7)(p25.3;q32.3) were mainly systemic (71%, 5/7) against just two pcALCL. In general, they lose CD3 (50% positive) and p-STAT3 (25% positive) expression, being all of them BCL2 positive. Moreover, in 60% of them other gene fusions were found. At the transcriptional level, they were characterized by the overexpression of TCF3 (TCF7L1/E2A), DLL3, CD58 and BCL2 genes. 75%(6/8) of pcALCL with 6p25.3 rearrangement featured the so-called "biphasic morphologic pattern, which was not found in cutaneous involvement from systemic ALCL. 83% (5/6) of the pcALCL cases with the "biphasic morphologic pattern" showed the t(6,7)(p25.3;q32.3) rearrangement. ALK-negative ALCL cases with 6p25.3 rearrangement are a subgroup of tumours that are heterogeneous with respect to the presence or absence of the t(6,7)(p25.3;q32.3) translocation.
Collapse
Affiliation(s)
| | | | - Rocío Nieves Salgado
- Haematology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | | | - Carlos Santonja
- Pathology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Sandra Pérez Buira
- Pathology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Miguel A Piris
- Pathology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Luis Requena
- Dermatology Department, Hospital Universitario, Fundación Jiménez Díaz, Madrid, Spain
| | - Rebeca Manso
- Pathology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
| | | |
Collapse
|
5
|
López-Nevado M, Ortiz-Martín J, Serrano C, Pérez-Saez MA, López-Lorenzo JL, Gil-Etayo FJ, Rodríguez-Frías E, Cabrera-Marante O, Morales-Pérez P, Rodríguez-Pinilla MS, Manso R, Salgado-Sánchez RN, Cerdá-Montagud A, Quesada-Espinosa JF, Gómez-Rodríguez MJ, Paz-Artal E, Muñoz-Calleja C, Arranz-Sáez R, Allende LM. Novel Germline TET2 Mutations in Two Unrelated Patients with Autoimmune Lymphoproliferative Syndrome-Like Phenotype and Hematologic Malignancy. J Clin Immunol 2023; 43:165-180. [PMID: 36066697 DOI: 10.1007/s10875-022-01361-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Accepted: 08/26/2022] [Indexed: 01/18/2023]
Abstract
Somatic mutations in the ten-eleven translocation methylcytosine dioxygenase 2 gene (TET2) have been associated to hematologic malignancies. More recently, biallelic, and monoallelic germline mutations conferring susceptibility to lymphoid and myeloid cancer have been described. We report two unrelated autoimmune lymphoproliferative syndrome-like patients who presented with T-cell lymphoma associated with novel germline biallelic or monoallelic mutations in the TET2 gene. Both patients presented a history of chronic lymphoproliferation with lymphadenopathies and splenomegaly, cytopenias, and immune dysregulation. We identified the first compound heterozygous patient for TET2 mutations (P1) and the first ALPS-like patient with a monoallelic TET2 mutation (P2). P1 had the most severe form of autosomal recessive disease due to TET2 loss of function resulting in absent TET2 expression and profound increase in DNA methylation. Additionally, the immunophenotype showed some alterations in innate and adaptive immune system as inverted myeloid/plasmacytoid dendritic cells ratio, elevated terminally differentiated effector memory CD8 + T-cells re-expressing CD45RA, regulatory T-cells, and Th2 circulating follicular T-cells. Double-negative T-cells, vitamin B12, and IL-10 were elevated according to the ALPS-like suspicion. Interestingly, the healthy P1's brother carried a TET2 mutation and presented some markers of immune dysregulation. P2 showed elevated vitamin B12, hypergammaglobulinemia, and decreased HDL levels. Therefore, novel molecular defects in TET2 confirm and expand both clinical and immunological phenotype, contributing to a better knowledge of the bridge between cancer and immunity.
Collapse
Affiliation(s)
- Marta López-Nevado
- Immunology Department, University Hospital 12 de Octubre, Av de Córdoba s/n, 28041, Madrid, Spain.
- Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.
| | | | - Cristina Serrano
- Immunology Department, University Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - María A Pérez-Saez
- Hematology Department, University Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - José L López-Lorenzo
- Hematology Department, University Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - Francisco J Gil-Etayo
- Immunology Department, University Hospital 12 de Octubre, Av de Córdoba s/n, 28041, Madrid, Spain
- Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Edgar Rodríguez-Frías
- Immunology Department, University Hospital 12 de Octubre, Av de Córdoba s/n, 28041, Madrid, Spain
- Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Oscar Cabrera-Marante
- Immunology Department, University Hospital 12 de Octubre, Av de Córdoba s/n, 28041, Madrid, Spain
- Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Pablo Morales-Pérez
- Immunology Department, University Hospital 12 de Octubre, Av de Córdoba s/n, 28041, Madrid, Spain
- Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain
| | | | - Rebeca Manso
- Pathology Department, Research Institute Fundación Jiménez Díaz, Madrid, Spain
| | | | - Ana Cerdá-Montagud
- Hematology Department, University Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - Juan F Quesada-Espinosa
- Genetics Department, University Hospital 12 de Octubre, Madrid, Spain
- UDisGen (Unidad de Dismorfología Y Genética), University Hospital 12 de Octubre, Madrid, Spain
| | - María J Gómez-Rodríguez
- Genetics Department, University Hospital 12 de Octubre, Madrid, Spain
- UDisGen (Unidad de Dismorfología Y Genética), University Hospital 12 de Octubre, Madrid, Spain
| | - Estela Paz-Artal
- Immunology Department, University Hospital 12 de Octubre, Av de Córdoba s/n, 28041, Madrid, Spain
- Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain
- School of Medicine, Complutense University of Madrid, Madrid, Spain
- CIBERINFEC, ISCIII, Madrid, Spain
| | - Cecilia Muñoz-Calleja
- Immunology Department, University Hospital La Princesa, Madrid, Spain
- School of Medicine, University Autónoma de Madrid, Madrid, Spain
- Research Institute Hospital de La Princesa, Madrid, Spain
| | - Reyes Arranz-Sáez
- Hematology Department, University Hospital La Princesa, Madrid, Spain
| | - Luis M Allende
- Immunology Department, University Hospital 12 de Octubre, Av de Córdoba s/n, 28041, Madrid, Spain.
- Research Institute Hospital 12 de Octubre (imas12), Madrid, Spain.
- School of Medicine, Complutense University of Madrid, Madrid, Spain.
| |
Collapse
|
6
|
Machan S, Alonso-Dominguez JM, Sánchez García FJ, Nieves Salgado R, Soto C, Castro Y, Pajares R, Manso R, Santonja C, Serrano Del Castillo C, Piris MA, Requena L, Rodríguez Pinilla SM. Plasmacytoid Dendritic Cell Dermatosis Associated to Myeloproliferative/Myelodysplastic Neoplasms. Am J Surg Pathol 2022; 46:1623-1632. [PMID: 36001453 DOI: 10.1097/pas.0000000000001960] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Cutaneous lesions in the setting of myeloproliferative neoplasms and myelodysplastic syndromes are poorly understood. We report 6 patients with pruritic papular eruptions composed of mature T-lymphocytes with large clusters of CD123-positive cells. Double immunohistochemical studies demonstrated a lack of myeloid cell nuclear differentiation antigen in the CD123-positive cells, which expressed SPIB, confirming that they were mature plasmacytoid dendritic cells. Four patients were diagnosed with chronic myelomonocytic leukemia and 2 with myelodysplastic syndromes (AREB-I and myelodysplastic syndromes with 5q deletion, respectively). All patients had a long history of hematological alterations, mainly thrombocytopenia, preceding the cutaneous disorder. Nevertheless, the skin lesions developed in all cases coincidentally with either progression or full-establishment of their hematological disease. Most cutaneous lesions disappeared spontaneously or after corticosteroid treatment. Molecular studies performed in both bone marrow and cutaneous lesions in 2 patients demonstrated the same mutational profile, confirming the specific, neoplastic nature of these mature plasmacytoid dendritic cells-composed cutaneous lesions.
Collapse
Affiliation(s)
| | | | | | | | | | - Yolanda Castro
- Pathology Department, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
| | - Raquel Pajares
- Pathology Department, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
| | - Rebeca Manso
- Pathology Department, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
| | - Carlos Santonja
- Pathology Department, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
| | | | | | | | | |
Collapse
|
7
|
Santonja C, Sánchez-García FJ, Rodríguez-Rodríguez RN, Manso R, Requena L, Gil-Mateo MDP, Rodríguez-Pinilla SM. Double CD4/CD8-Positive, Nonpoikilodermic Mycosis Fungoides Expressing CD56 in a Young Man. Am J Dermatopathol 2022; 44:936-939. [PMID: 35925554 DOI: 10.1097/dad.0000000000002259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
ABSTRACT We report a case of mycosis fungoides (MF) in an 18-year-old man whose neoplastic T cells expressed CD4, CD8, and CD56, with no evidence of TCR-delta or Epstein-Barr virus (EBER) expression. Clinically, neither hypopigmentation nor hyperpigmentation nor poikilodermatous skin lesions were present, and the lesions subsided with oral corticoids and retinoids and environmental solar ultraviolet exposure. Our case represents the oldest patient reported so far with nonpoikilodermatous, CD8/CD56 MF and adds to the phenotypic diversity of MF in the pediatric population. This distinct phenotype does not seem to be linked to a more aggressive course than the classic CD-4 positive one.
Collapse
Affiliation(s)
- Carlos Santonja
- PathologyDepartment, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | | | | | - Rebeca Manso
- PathologyDepartment, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Luis Requena
- DermatologyDepartment, Hospital Universitario Fundación Jiménez Diaz, Madrid, Spain; and
| | | | | |
Collapse
|
8
|
Prieto-Potin I, Idrovo F, Suárez-Gauthier A, Díaz-Blázquez M, Astilleros-Blanco de Córdova L, Chamizo C, Zazo S, Carvajal N, López-Sánchez A, Pérez-Buira S, Aúz-Alexandre CL, Manso R, Plaza-Sánchez J, de Lucas-López V, Pérez-González N, Martín-Valle S, Cristóbal I, Casado V, García-Foncillas J, Rojo F. Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors. Diagnostics (Basel) 2022; 12:diagnostics12081903. [PMID: 36010253 PMCID: PMC9406465 DOI: 10.3390/diagnostics12081903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Revised: 07/22/2022] [Accepted: 08/03/2022] [Indexed: 11/25/2022] Open
Abstract
Gynecological cancer accounts for an elevated incidence worldwide requiring responsiveness regarding its care. The comprehensive genomic approach agrees with the classification of certain tumor types. We evaluated 49 patients with gynecological tumors undergoing high-throughput sequencing to explore whether identifying alterations in cancer-associated genes could characterize concrete histological subtypes. We performed immune examination and analyzed subsequent clinical impact. We found 220 genomic aberrations mostly distributed as single nucleotide variants (SNV, 77%). Only 3% were classified as variants of strong clinical significance in BRCA1 and BRCA2 of ovarian high-grade serous (HGSC) and uterine endometrioid carcinoma. TP53 and BRCA1 occurred in 72% and 28% of HGSC. Cervical squamous cell carcinoma was entirely HPV-associated and mutations occurred in PIK3CA (60%), as well as in uterine serous carcinoma (80%). Alterations were seen in PTEN (71%) and PIK3CA (60%) of uterine endometrioid carcinoma. Elevated programmed death-ligand 1 (PD-L1) was associated with high TILs. Either PD-L1 augmented in deficient mis-matched repair (MMR) proteins or POLE mutated cases when compared to a proficient MMR state. An 18% received genotype-guided therapy and a 4% immunotherapy. The description of tumor subtypes is plausible through high-throughput sequencing by recognizing clinically relevant alterations. Additional concomitant assessment of immune biomarkers identifies candidates for immunotherapy.
Collapse
Affiliation(s)
- Iván Prieto-Potin
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Franklin Idrovo
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Ana Suárez-Gauthier
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - María Díaz-Blázquez
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | | | - Cristina Chamizo
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Sandra Zazo
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Nerea Carvajal
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Almudena López-Sánchez
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Sandra Pérez-Buira
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Carmen Laura Aúz-Alexandre
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Rebeca Manso
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Jenifer Plaza-Sánchez
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Virginia de Lucas-López
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Nuria Pérez-González
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Sara Martín-Valle
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Ion Cristóbal
- Cancer Unit for Research on Novel Therapeutic Targets, Oncohealth Institute, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
- Translational Oncology Division, Oncohealth Institute, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Victoria Casado
- Translational Oncology Division, Oncohealth Institute, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Jesús García-Foncillas
- Cancer Unit for Research on Novel Therapeutic Targets, Oncohealth Institute, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
- Translational Oncology Division, Oncohealth Institute, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Federico Rojo
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
- Correspondence:
| |
Collapse
|
9
|
Rodríguez‐Pinilla SM, Salgado RN, Chamizo C, Santonja C, Stewart P, Carvajal N, McCafferty N, Manso R, Morillo D, Piris MÁ, González de Castro D. Redefining the high‐grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report. eJHaem 2022; 3:171-174. [PMID: 35846201 PMCID: PMC9175839 DOI: 10.1002/jha2.310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 09/14/2021] [Accepted: 09/20/2021] [Indexed: 11/05/2022]
Abstract
We report a patient initially diagnosed with a triple hit high‐grade B cell lymphoma (HGBL‐TH), in which further morphologic, immunohistochemical, and next‐generation sequencing studies of subsequent specimens disclosed it to be a germinal center diffuse large B cell lymphoma (GC‐DLBCL) with BCL2/BCL6 gene translocations, PVT1‐deletion, and gain of MYC genes evolving from a previous follicular lymphoma. However, fluorescence in situ hybridization (FISH) studies with the break‐apart probe for MYC gene showed a fusion and two separated signals (red and green, respectively) leading to the interpretation of MYC gene translocation and a false diagnosis of a TH‐lymphoma, according to the recent WHO classification. Nevertheless, PVT1 deletion plus MYC gain/amplification has been described as a cause of the double‐hi transcription profile. These data highlight the need for new criteria to identify these highly aggressive lymphomas.
Collapse
Affiliation(s)
| | - Rocío Nieves Salgado
- Cytogenetic Department Hospital Universitario Fundación Jiménez Díaz (FJD) Madrid Spain
| | - Cristina Chamizo
- Pathology Department Hospital Universitario Fundación Jiménez Díaz (FJD) Madrid Spain
| | - Carlos Santonja
- Pathology Department Hospital Universitario Fundación Jiménez Díaz (FJD) Madrid Spain
| | - Peter Stewart
- Patrick G Johnston Centre for Cancer Research Queen's University Belfast Belfast UK
| | - Nerea Carvajal
- Pathology Department Hospital Universitario Fundación Jiménez Díaz (FJD) Madrid Spain
| | - Neil McCafferty
- Patrick G Johnston Centre for Cancer Research Queen's University Belfast Belfast UK
| | - Rebeca Manso
- Pathology Department Hospital Universitario Fundación Jiménez Díaz (FJD) Madrid Spain
| | - Daniel Morillo
- Haematology Department Hospital Universitario Fundación Jiménez Díaz Madrid Spain
| | - Miguel Ángel Piris
- Pathology Department Hospital Universitario Fundación Jiménez Díaz (FJD) Madrid Spain
| | | |
Collapse
|
10
|
Tomas-Roca L, Rodriguez M, Alonso-Alonso R, Cereceda L, Rodríguez-Pinilla SM, Borregon J, Manso R, Villaescusa T, Córdoba R, Sánchez-Beato M, Fernández-Miranda I, Bárcena C, García JF, Mollejo M, García-Cosio M, Martin-Acosta P, Climent F, Caballero D, Piris MA. Mutational landscape of nodal peripheral T-cell lymphoma subtypes. Eur J Cancer 2021. [DOI: 10.1016/s0959-8049(21)00643-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Manso R, Rodriguez M, Chamizo C, Pérez N, Alonso‐Alonso R, Minguez PA, Borregon J, Baez‐Duran E, Casas‐del Pozo EM, Piris MA, Rojo F, Rodriguez‐Pinilla SM. INTESTINAL T‐CELL LYMPHOMAS: MOLECULAR INTEGRATIVE ANALYSIS RECOGNIZES DIFFERENT THERAPEUTIC TARGETS FOR EACH SUBTYPE. Hematol Oncol 2021. [DOI: 10.1002/hon.13_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- R Manso
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - M Rodriguez
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - C Chamizo
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - N Pérez
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | | | - P. A Minguez
- Fundacion Jimenez Diaz Genetics and Genomics Department and Bioinformatics Unit Madrid Spain
| | - J Borregon
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | | | | | - M. A Piris
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - F Rojo
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | | |
Collapse
|
12
|
Machan S, Rodriguez M, Manso R, Borregon J, Chamizo C, Alonso‐Alonso R, Pérez Buira S, Rodríguez‐Peralto JL, Cerroni L, Cereceda L, Córdoba R, Án. Piris M, Requena L, María Rodríguez‐Pinilla S. SUBCUTANEOUS PANNICULITIS‐LIKE T‐CELL LYMPHOMA: MOLECULAR AND MUTATIONAL CHARACTERIZATION COMPARED WITH LUPUS PANNICULITIS AND HISTOPATHOLOGIC OVERLAPPING CASES. Hematol Oncol 2021. [DOI: 10.1002/hon.138_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S Machan
- Fundación Jiménez Díaz‐Universidad Autónoma de Madrid, Dermatology Madrid Spain
| | - M Rodriguez
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - R Manso
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - J Borregon
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - C Chamizo
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | | | | | | | - L Cerroni
- Medical University of Graz, Dermatology Graz Austria
| | - L Cereceda
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - R Córdoba
- Fundación Jiménez Díaz, Hematology Madrid Spain
| | - M Án. Piris
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - L Requena
- Fundación Jiménez Díaz‐Universidad Autónoma de Madrid, Dermatology Madrid Spain
| | | |
Collapse
|
13
|
Machan S, Rodríguez M, Alonso-Alonso R, Manso R, Pérez-Buira S, Borregón J, Rodríguez-Peralto JL, Cerroni L, Haro R, García C, García Toro E, Estrach T, García-Herrera A, Ferrer B, González-Cruz C, Segues N, Afonso-Martin JL, Peñate Y, Monteagudo C, Limeres-Gonzalez MÁ, González-Núñez MÁ, Torres MÁTN, Cereceda L, Córdoba R, Piris MÁ, Requena L, María Rodríguez-Pinilla S. Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes. Leuk Lymphoma 2021; 62:2130-2140. [PMID: 33966586 DOI: 10.1080/10428194.2021.1901098] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare cytotoxic cutaneous lymphoma. Differential diagnosis with lupus erythematosus panniculitis (LEP) can be challenging and overlapping cases have been described. In this study, we investigate whether gene expression profiling may or not identify markers that can be used to improve our understanding of the disease and to make a precise differential diagnosis. SPTCL, LEP, and overlapping cases were analyzed using a customized NanoString platform including 208 genes related to T-cell differentiation, stromal signatures, oncogenes, and tumor suppressor genes. Gene expression unsupervised analysis of the samples differentiated SPTCL from LEP samples. Most overlapping cases were clustered with LEP cases. Differentially expressed genes were observed when comparing SPTCL with LEP cases; and overlapping with LEP cases. Gene set enrichment analysis recognized gene sets defining each group. In conclusion, SPTCL and LEP have distinctive molecular profiles and the molecular background of overlapping cases more closely resembles LEP.
Collapse
Affiliation(s)
- Salma Machan
- Department of Dermatology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - Marta Rodríguez
- Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.,CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain
| | - Ruth Alonso-Alonso
- Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.,CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain
| | - Rebeca Manso
- Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.,CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain
| | - Sandra Pérez-Buira
- Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.,CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain
| | - Jennifer Borregón
- Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.,CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain
| | | | - Lorenzo Cerroni
- Department of Dermatology, Dermatopathology Research Unit, Medical University of Graz, Graz, Austria
| | - Rosario Haro
- Department of Dermatology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | | | | | | | | | | | | | - Nerea Segues
- Hospital Universitario Donostia, San Sebastián, Spain
| | - Juan Luis Afonso-Martin
- Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain
| | - Yeray Peñate
- Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Spain
| | - Carlos Monteagudo
- Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, Spain
| | | | | | | | - Laura Cereceda
- Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.,CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain
| | - Raúl Córdoba
- Department of Hematology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - Miguel Ángel Piris
- Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.,CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain
| | - Luis Requena
- Department of Dermatology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - Socorro María Rodríguez-Pinilla
- Department of Pathology, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain.,CIBERONC (Centro de Investigación Biomédica en Red de Cáncer), Madrid, Spain
| |
Collapse
|
14
|
Manso R, Rodríguez-Perales S, Torres-Ruiz R, Santonja C, Rodríguez-Pinilla SM. PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements. Leuk Lymphoma 2021; 62:1648-1656. [PMID: 33550887 DOI: 10.1080/10428194.2021.1881511] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Nodal peripheral T-cell lymphomas (n-PTCL) are aggressive lymphomas with no specific treatment. Programmed death 1 (PD-1) inhibits T-cell activation and proliferation, and the expression of its ligand PD-L1 has been associated with worse prognosis in some tumors. We performed immunohistochemistry for PD-1, p-STAT3, and PD-L1 (Clones SP142/263/22C3/28.8) and FISH studies for PD-L1/2 genes in chromosome 9p in a series of 168 formalin-fixed, paraffin-embedded n-PTCL samples. PD-L1 (clone 263) was the most frequently detected in both tumor cells (especially in the ALCL subgroup) and the microenvironment (especially in the AITL subgroup). In five ALCL cases, 3-4 copies of the two loci of chromosome 9 were found, suggestive of polyploidy. PD-L1 correlated with p-STAT3 on tumor cells. PD-1 expression in tumor cells was related to expression of PD-L1 in microenvironment. The expression of PD-L1 on tumor cells or microenvironment suggests that some n-PTCL cases might benefit from immune check-point modulation therapy.
Collapse
Affiliation(s)
- Rebeca Manso
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Sandra Rodríguez-Perales
- Molecular Cytogenetics and Genome Engineering Group, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
| | - Raúl Torres-Ruiz
- Molecular Cytogenetics and Genome Engineering Group, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
| | - Carlos Santonja
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | | |
Collapse
|
15
|
Prieto-Potin I, Carvajal N, Plaza-Sánchez J, Manso R, Aúz-Alexandre CL, Chamizo C, Zazo S, López-Sánchez A, Rodríguez-Pinilla SM, Camacho L, Longarón R, Bellosillo B, Somoza R, Hernández-Losa J, Fernández-Soria VM, Ramos-Ruiz R, Cristóbal I, García-Foncillas J, Rojo F. Validation and clinical application of a targeted next-generation sequencing gene panel for solid and hematologic malignancies. PeerJ 2020; 8:e10069. [PMID: 33083132 PMCID: PMC7546223 DOI: 10.7717/peerj.10069] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Accepted: 09/09/2020] [Indexed: 01/29/2023] Open
Abstract
Background Next-generation sequencing (NGS) is a high-throughput technology that has become widely integrated in molecular diagnostics laboratories. Among the large diversity of NGS-based panels, the Trusight Tumor 26 (TsT26) enables the detection of low-frequency variants across 26 genes using the MiSeq platform. Methods We describe the inter-laboratory validation and subsequent clinical application of the panel in 399 patients presenting a range of tumor types, including gastrointestinal (GI, 29%), hematologic (18%), lung (13%), gynecological and breast (8% each), among others. Results The panel is highly accurate with a test sensitivity of 92%, and demonstrated high specificity and positive predictive values (95% and 96%, respectively). Sequencing testing was successful in two-thirds of patients, while the remaining third failed due to unsuccessful quality-control filtering. Most detected variants were observed in the TP53 (28%), KRAS (16%), APC (10%) and PIK3CA (8%) genes. Overall, 372 variants were identified, primarily distributed as missense (81%), stop gain (9%) and frameshift (7%) altered sequences and mostly reported as pathogenic (78%) and variants of uncertain significance (19%). Only 14% of patients received targeted treatment based on the variant determined by the panel. The variants most frequently observed in GI and lung tumors were: KRAS c.35G > A (p.G12D), c.35G > T (p.G12V) and c.34G > T (p.G12C). Conclusions Prior panel validation allowed its use in the laboratory daily practice by providing several relevant and potentially targetable variants across multiple tumors. However, this study is limited by high sample inadequacy rate, raising doubts as to continuity in the clinical setting.
Collapse
Affiliation(s)
- Iván Prieto-Potin
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Nerea Carvajal
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Jenifer Plaza-Sánchez
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Rebeca Manso
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Carmen Laura Aúz-Alexandre
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Cristina Chamizo
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Sandra Zazo
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Almudena López-Sánchez
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | | | - Laura Camacho
- Department of Pathology, Hospital Del Mar Medical Research Institute, Barcelona, Spain
| | - Raquel Longarón
- Department of Pathology, Hospital Del Mar Medical Research Institute, Barcelona, Spain
| | - Beatriz Bellosillo
- Department of Pathology, Hospital Del Mar Medical Research Institute, Barcelona, Spain
| | - Rosa Somoza
- Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain
| | | | | | | | - Ion Cristóbal
- Translational Oncology Division, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Jesús García-Foncillas
- Translational Oncology Division, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Federico Rojo
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| |
Collapse
|
16
|
Rodríguez-Pinilla SM, Santonja C, Stewart P, Carvajal N, McCafferty N, Manso R, Meizoso T, Caro Gutiérrez MD, Piris MÁ, González de Castro D. Indolent clinical behaviour of primary cutaneous diffuse large B-cell lymphoma, leg type, with double MYC and BCL6 gene rearrangement. Br J Haematol 2020; 191:e83-e86. [PMID: 32780869 DOI: 10.1111/bjh.17038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
| | - Carlos Santonja
- Pathology Department, Hospital Universitario Fundación Jiménez Díaz (FJD), Madrid, Spain
| | - Peter Stewart
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK
| | - Nerea Carvajal
- Pathology Department, Hospital Universitario Fundación Jiménez Díaz (FJD), Madrid, Spain
| | - Neil McCafferty
- Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, UK
| | - Rebeca Manso
- Pathology Department, Hospital Universitario Fundación Jiménez Díaz (FJD), Madrid, Spain
| | - Telma Meizoso
- Pathology Department, Hospital Universitario de Móstoles, Madrid, Spain
| | | | - Miguel Ángel Piris
- Pathology Department, Hospital Universitario Fundación Jiménez Díaz (FJD), Madrid, Spain
| | | |
Collapse
|
17
|
Prieto-Torres L, Trascasa Á, Manso R, Machan S, Cieza-Diaz D, Olmedilla G, García-García M, Ara-Martín M, Requena L, Piris MÁ, Rodríguez-Pinilla SM. Two independent consecutive lymphoma cases carry an identical MYD88 mutation but differ in their IGVH rearrangement. Br J Haematol 2020; 190:e352-e356. [PMID: 32578872 DOI: 10.1111/bjh.16917] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
| | - Álvaro Trascasa
- Department of Pathology, Fundación Jimenez Diaz, Madrid, Spain
| | - Rebeca Manso
- Department of Pathology, Fundación Jimenez Diaz, Madrid, Spain
| | - Salma Machan
- Department of Dermatology, Fundación Jimenez Diaz, Madrid, Spain
| | - Deisy Cieza-Diaz
- Department of Dermatology, Fundación Jimenez Diaz, Madrid, Spain
| | - Gabriel Olmedilla
- Department of Pathology Hospital, Universitario La Paz, Madrid, Spain
| | - Mar García-García
- Department of Pathology, Hospital Clínico Lozano Blesa, Zaragoza, Spain
| | - Mariano Ara-Martín
- Department of Dermatology, Hospital Clínico Lozano Blesa, Zaragoza, Spain
| | - Luis Requena
- Department of Dermatology, Fundación Jimenez Diaz, Madrid, Spain
| | - Miguel Á Piris
- Department of Pathology, Fundación Jimenez Diaz, Madrid, Spain
| | | |
Collapse
|
18
|
Camacho Castañeda FI, Dotor A, Manso R, Martín P, Prieto Pareja E, Palomo Esteban T, García Vela JA, Santonja C, Piris MA, Rodríguez Pinilla SM. Epstein-Barr virus-associated large B-cell lymphoma transformation in marginal zone B-cell lymphoma: a series of four cases. Histopathology 2020; 77:112-122. [PMID: 32145092 DOI: 10.1111/his.14101] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2019] [Revised: 02/07/2020] [Accepted: 03/02/2020] [Indexed: 12/11/2022]
Abstract
AIMS To present four examples of clonally related Epstein-Barr virus (EBV)-associated large-cell transformation of marginal zone lymphoma (MZL) (of nodal, extranodal and splenic types), occurring 120, 11 and 5 months after the initial diagnosis in three instances, and concurrently in one case; and to discuss several interesting features of EBV infection. METHODS AND RESULTS Somatic mutations were detected by use of a customised panel for next-generation sequencing and polymerase chain reaction studies of IgH in both low-grade and high-grade components of each case. In case 1, the initial biopsy of nodal MZL showed scattered EBV-positive cells, which might constitute an indication of EBV-induced progression. Case 2 showed heterogeneous EBV expression, a phenomenon attributable to loss of the EBV episomes during cell division, or to a secondary superinfection or reactivation of the virus. In case 3, p53 overexpression related to gene mutation and EBV-encoded small RNAs were identified in the same neoplastic component. In case 4, the mucosa-associated lymphoid tissue-type MZL and the high-grade component were identified concurrently in a patient previously treated with methotrexate for an autoimmune disorder. CONCLUSION These data suggest that the presence of EBV should be added to the list of potential markers to be analysed for MZL prognosis.
Collapse
Affiliation(s)
| | - Ana Dotor
- Pathology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain
| | | | - Paloma Martín
- Pathology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
19
|
Prieto-Torres L, Manso R, Cieza D, Jo M, Pérez LK, Montenegro-Damaso T, Eraña I, Lorda M, Massa DS, Machan S, Córdoba R, Ara M, Requena L, Rodriguez-Pinilla SM, Piris MA. Large cells with CD30 expression and Hodgkin-like features in primary cutaneous marginal zone B-cell lymphoma: a study of 13 cases. Eur J Cancer 2019. [DOI: 10.1016/s0959-8049(19)30574-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Manso R, Martínez-Magunacelaya N, Eraña-Tomás I, Monsalvez V, Rodríguez-Peralto JL, Ortiz-Romero PL, Santonja C, Cristóbal I, Piris MA, Rodríguez-Pinilla SM. Mycosis fungoides progression could be regulated by microRNAs. PLoS One 2018; 13:e0198477. [PMID: 29894486 PMCID: PMC5997347 DOI: 10.1371/journal.pone.0198477] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2018] [Accepted: 05/18/2018] [Indexed: 12/26/2022] Open
Abstract
Differentiating early mycosis fungoides (MF) from inflammatory dermatitis is a challenge. We compare the differential expression profile of early-stage MF samples and benign inflammatory dermatoses using microRNA (miRNA) arrays. 114 miRNAs were found to be dysregulated between these entities. The seven most differentially expressed miRNAs between these two conditions were further analyzed using RT-PCR in two series comprising 38 samples of early MFs and 18 samples of inflammatory dermatitis. A series of 51 paraffin-embedded samples belonging to paired stages of 16 MF patients was also analyzed. MiRNAs 26a, 222, 181a and 146a were differentially expressed between tumoral and inflammatory conditions. Two of these miRNAs (miRNA-181a and miRNA-146a) were significantly deregulated between early and advanced MF stages. Bioinformatic analysis showed FOXP3 expression to be regulated by these miRNAs. Immunohistochemistry revealed the level of FOXP3 expression to be lower in tumoral MFs than in plaque lesions in paraffin-embedded tissue. A functional study confirmed that both miRNAs diminished FOXP3 expression when overexpressed in CTCL cells. The data presented here suggest that the analysis of a restricted number of miRNAs (26a, 222, 181a and 146a) could be sufficient to differentiate tumoral from reactive conditions. Moreover, these miRNAs seem to be involved in MF progression.
Collapse
Affiliation(s)
- Rebeca Manso
- Pathology Department, Fundación Jiménez Díaz, UAM, Madrid, CIBERONC, Madrid, Spain
| | | | | | - Verónica Monsalvez
- Hospital Universitario 12 de Octubre, Dermatology Department, Madrid, Spain
| | | | | | - Carlos Santonja
- Pathology Department, Fundación Jiménez Díaz, UAM, Madrid, CIBERONC, Madrid, Spain
| | - Ion Cristóbal
- Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Miguel A. Piris
- Pathology Department, Fundación Jiménez Díaz, UAM, Madrid, CIBERONC, Madrid, Spain
| | | |
Collapse
|
21
|
Manso R, Sánchez-Beato M, González-Rincón J, Gómez S, Rojo F, Mollejo M, García-Cosio M, Menárguez J, Piris MA, Rodríguez-Pinilla SM. Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma. Br J Haematol 2017; 183:497-501. [PMID: 29076126 DOI: 10.1111/bjh.14984] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- Rebeca Manso
- Pathology Department, Fundación Jiménez Díaz, UAM, Madrid, Spain
| | | | - Julia González-Rincón
- Instituto Investigación Sanitaria Puerta de Hierro-Majadahonda (IDIPHIM), Madrid, Spain.,Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain
| | - Sagrario Gómez
- Instituto Investigación Sanitaria Puerta de Hierro-Majadahonda (IDIPHIM), Madrid, Spain
| | - Federico Rojo
- Pathology Department, Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Manuela Mollejo
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.,Pathology Department, Hospital Universitario Virgen de la Salud, Toledo, Spain
| | - Mónica García-Cosio
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.,Pathology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - Javier Menárguez
- Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain.,Pathology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - Miguel A Piris
- Pathology Department, Fundación Jiménez Díaz, UAM, Madrid, Spain.,Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain
| | - Socorro M Rodríguez-Pinilla
- Pathology Department, Fundación Jiménez Díaz, UAM, Madrid, Spain.,Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid, Spain
| |
Collapse
|
22
|
Manso R, Martínez-Magunacelaya N, Chamizo C, Rojo F, Piris MÁ, Rodriguez-Pinilla SM. Mutual regulation between BCL6 and a specific set of miRNAs controls TFH
phenotype in peripheral T-cell lymphoma. Br J Haematol 2017; 182:587-590. [DOI: 10.1111/bjh.14824] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Rebeca Manso
- Pathology Department; IIS-Fundación Jiménez Díaz; UAM; Madrid Spain
| | | | - Cristina Chamizo
- Pathology Department; IIS-Fundación Jiménez Díaz; UAM; Madrid Spain
| | - Federico Rojo
- Pathology Department; IIS-Fundación Jiménez Díaz; UAM; Madrid Spain
| | | | | |
Collapse
|
23
|
Alegría-Landa V, Prieto-Torres L, Santonja C, Córdoba R, Manso R, Requena L, Rodríguez-Pinilla SM. MYD88L265P mutation in cutaneous involvement by Waldenström macroglobulinemia. J Cutan Pathol 2017; 44:625-631. [DOI: 10.1111/cup.12944] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2016] [Revised: 02/23/2017] [Accepted: 03/22/2017] [Indexed: 12/31/2022]
Affiliation(s)
| | - Lucía Prieto-Torres
- Department of Pathology; Hospital Clínico Universitario Lozano Blesa; Zaragoza Spain
| | - Carlos Santonja
- Lymphoma Unit, Oncohealth Institute; Fundación Jiménez Díaz, Universidad Autónoma; Madrid Spain
| | - Raul Córdoba
- Department of Hematology; Fundación Jiménez Díaz, Universidad Autónoma; Madrid Spain
| | - Rebeca Manso
- Lymphoma Unit, Oncohealth Institute; Fundación Jiménez Díaz, Universidad Autónoma; Madrid Spain
| | - Luis Requena
- Department of Dermatology, Fundación Jiménez Díaz; Universidad Autónoma; Madrid Spain
| | | |
Collapse
|
24
|
Rincón R, Zazo S, Chamizo C, Manso R, González-Alonso P, Martín-Aparicio E, Cristóbal I, Cañadas C, Perona R, Lluch A, Eroles P, García-Foncillas J, Albanell J, Rovira A, Madoz-Gúrpide J, Rojo F. c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer. Mol Cancer Ther 2016; 15:2780-2790. [PMID: 27599524 DOI: 10.1158/1535-7163.mct-15-0920] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Accepted: 08/07/2016] [Indexed: 11/16/2022]
Abstract
MAPK phosphatase-1 (MKP-1) is overexpressed during malignant transformation of the breast in many patients, and it is usually associated with chemoresistance through interference with JNK-driven apoptotic pathways. Although the molecular settings of the mechanism have been documented, details about the contribution of MKP-1 to the failure of chemotherapeutic interventions are unclear. Transient overexpression of MKP-1 and treatment with JNK-modulating agents in breast carcinoma cells confirmed the mediation of MKP-1 in the resistance to taxanes and anthracyclines in breast cancer, through the inactivation of JNK1/2. We next assessed MKP-1 expression and JNK1/2 phosphorylation status in a large cohort of samples from 350 early breast cancer patients treated with adjuvant anthracycline-based chemotherapy. We detected that MKP-1 overexpression is a recurrent event predominantly linked to dephosphorylation of JNK1/2 with an adverse impact on relapse of the tumor and overall and disease-free survival. Moreover, MKP-1 and p-JNK1/2 determinations in 64 locally advanced breast cancer patients treated with neoadjuvant taxane-based chemotherapy showed an inverse correlation between MKP-1 overexpression (together with JNK1/2 inhibition) and the pathologic response of the tumors. Our results emphasize the importance of MKP-1 as a potential predictive biomarker for a subset of breast cancer patients with worse outcome and less susceptibility to treatment. Mol Cancer Ther; 15(11); 2780-90. ©2016 AACR.
Collapse
Affiliation(s)
- Raúl Rincón
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Sandra Zazo
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Cristina Chamizo
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Rebeca Manso
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | | | | | - Ion Cristóbal
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - Carmen Cañadas
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Rosario Perona
- "Alberto Sols" Biomedical Research Institute CSIC-UAM, Madrid, Spain
| | - Ana Lluch
- Institute of Health Research INCLIVA, Valencia, Spain
| | - Pilar Eroles
- Institute of Health Research INCLIVA, Valencia, Spain
| | - Jesús García-Foncillas
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - Joan Albanell
- Medical Oncology Department, Hospital del Mar, Barcelona, Spain
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Ana Rovira
- Medical Oncology Department, Hospital del Mar, Barcelona, Spain
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain
| | | | - Federico Rojo
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain.
| |
Collapse
|
25
|
Cristóbal I, Torrejón B, González-Alonso P, Manso R, Rojo F, García-Foncillas J. Downregulation of miR-138 as a Contributing Mechanism to Lcn-2 Overexpression in Colorectal Cancer with Liver Metastasis. World J Surg 2016; 40:1021-2. [PMID: 26316117 DOI: 10.1007/s00268-015-3241-z] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Affiliation(s)
- Ion Cristóbal
- Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", Avda. Reyes Católicos-2, 28040, Madrid, Spain.
| | - Blanca Torrejón
- Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", Avda. Reyes Católicos-2, 28040, Madrid, Spain
| | - Paula González-Alonso
- Pathology Department, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", 28040, Madrid, Spain
| | - Rebeca Manso
- Pathology Department, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", 28040, Madrid, Spain
| | - Federico Rojo
- Pathology Department, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", 28040, Madrid, Spain
| | - Jesús García-Foncillas
- Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", Avda. Reyes Católicos-2, 28040, Madrid, Spain.
| |
Collapse
|
26
|
Cristóbal I, Madoz-Gúrpide J, Manso R, González-Alonso P, Rojo F, García-Foncillas J. Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review. Curr Med Res Opin 2016; 32:1137-41. [PMID: 26950691 DOI: 10.1185/03007995.2016.1162774] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
FTY720 (Fingolimod, Gilenya (†) ) is an FDA-approved immunosuppressant currently used in the treatment of multiple sclerosis. However, a large number of studies over the last few years have shown that FTY720 shows potent antitumor properties that suggest its potential usefulness as a novel anticancer agent. Interestingly, the restoration of protein phosphatase 2A (PP2A) activity mediated by FTY720 could play a key role in its antitumor effects. Taking into account that PP2A inactivation is a common event that determines poor outcome in several tumor types, FTY720 could serve as an alternative therapeutic strategy for cancer patients with such alterations.
Collapse
Affiliation(s)
- Ion Cristóbal
- a Translational Oncology Division , Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, University Hospital 'Fundacion Jimenez Diaz' , Madrid , Spain
| | | | - Rebeca Manso
- b Pathology Department , IIS 'Fundacion Jimenez Diaz' , Madrid , Spain
| | | | - Federico Rojo
- b Pathology Department , IIS 'Fundacion Jimenez Diaz' , Madrid , Spain
| | - Jesús García-Foncillas
- a Translational Oncology Division , Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, University Hospital 'Fundacion Jimenez Diaz' , Madrid , Spain
| |
Collapse
|
27
|
Manso R, Bellas C, Martín-Acosta P, Mollejo M, Menárguez J, Rojo F, Llamas P, Piris MA, Rodríguez-Pinilla SM. C-MYC is related to GATA3 expression and associated with poor prognosis in nodal peripheral T-cell lymphomas. Haematologica 2016; 101:e336-8. [PMID: 27151990 DOI: 10.3324/haematol.2016.143768] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Affiliation(s)
- Rebeca Manso
- Pathology Department, Fundación Jiménez Díaz, UAM, Madrid
| | - Carmen Bellas
- Pathology Department, Hospital Universitario Puerta de Hierro, Madrid
| | | | - Manuela Mollejo
- Pathology Department, Hospital Universitario Virgen de la Salud, Toledo
| | - Javier Menárguez
- Pathology Department, Hospital Universitario Gregorio Marañón, Madrid
| | - Federico Rojo
- Pathology Department, Fundación Jiménez Díaz, UAM, Madrid
| | - Pilar Llamas
- Haematology Department, Fundación Jiménez Díaz, UAM, Madrid
| | - Miguel A Piris
- Pathology Department, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, IDIVAL, Santander, Spain
| | | |
Collapse
|
28
|
Manso R, Roncador G, Montes-Moreno S, Rojo F, Pérez-Sáenz MÁ, Mollejo M, Menárguez J, Carvajal N, García-Cosio M, Llamas P, Piris MA, Rodríguez-Pinilla SM. p-MAPK1 expression associated with poor prognosis in angioimmunoblastic T-cell lymphoma patients. Br J Haematol 2016; 176:661-664. [PMID: 26915336 DOI: 10.1111/bjh.13972] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- Rebeca Manso
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Giovanna Roncador
- Monoclonal Antibodies Core Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Santiago Montes-Moreno
- Pathology Department, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, IDIVAL, Santander, Spain
| | - Federico Rojo
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | | | - Manuela Mollejo
- Pathology Department, Hospital Universitario Virgen de la Salud, Toledo, Spain
| | - Javier Menárguez
- Pathology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain
| | - Nerea Carvajal
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | | | - Pilar Llamas
- Haematology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Miguel A Piris
- Pathology Department, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, IDIVAL, Santander, Spain
| | | |
Collapse
|
29
|
Rincón R, Cristóbal I, Zazo S, Arpí O, Menéndez S, Manso R, Lluch A, Eroles P, Rovira A, Albanell J, García-Foncillas J, Madoz-Gúrpide J, Rojo F. PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. Oncotarget 2015; 6:4299-314. [PMID: 25726524 PMCID: PMC4414191 DOI: 10.18632/oncotarget.3012] [Citation(s) in RCA: 82] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2014] [Accepted: 12/31/2014] [Indexed: 11/26/2022] Open
Abstract
The protein phosphatase 2A (PP2A) is a key tumor suppressor which has emerged as a novel molecular target in some human cancers. Here, we show that PP2A inhibition is a common event in breast cancer and identified PP2A phosphorylation and deregulation SET and CIP2A as molecular contributing mechanisms to inactivate PP2A. Interestingly, restoration of PP2A activity after FTY720 treatment reduced cell growth, induced apoptosis and decreased AKT and ERK activation. Moreover, FTY720 led to PP2A activation then enhancing doxorubicin-induced antitumor effects both in vitro and in vivo. PP2A inhibition (CPscore: PP2A phosphorylation and/or CIP2A overexpression) was detected in 27% of cases (62/230), and associated with grade (p = 0.017), relapse (p < 0.001), negative estrogen (p < 0.001) and progesterone receptor expression (p < 0.001), HER2-positive tumors (p = 0.049), Ki-67 expression (p < 0.001), and higher AKT (p < 0.001) and ERK (p < 0.001) phosphorylation. Moreover, PP2A inhibition determined shorter overall (p = 0.006) and event-free survival (p = 0.003), and multivariate analysis confirmed its independent prognostic impact. Altogether, our results indicate that PP2A is frequently inactivated in breast cancer and determines worse outcome, and its restoration using PP2A activators represents an alternative therapeutic strategy in this disease.
Collapse
Affiliation(s)
- Raúl Rincón
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital "Fundación Jiménez Diaz", Madrid, Spain
| | - Ion Cristóbal
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital "Fundación Jiménez Diaz", Madrid, Spain
| | - Sandra Zazo
- Pathology Department, IIS "Fundación Jiménez Diaz", Madrid, Spain
| | - Oriol Arpí
- Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Silvia Menéndez
- Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Rebeca Manso
- Pathology Department, IIS "Fundación Jiménez Diaz", Madrid, Spain
| | - Ana Lluch
- Institute of Health Research INCLIVA, Valencia, Spain
| | - Pilar Eroles
- Institute of Health Research INCLIVA, Valencia, Spain
| | - Ana Rovira
- Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Joan Albanell
- Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Jesús García-Foncillas
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital "Fundación Jiménez Diaz", Madrid, Spain
| | | | - Federico Rojo
- Pathology Department, IIS "Fundación Jiménez Diaz", Madrid, Spain.,Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| |
Collapse
|
30
|
Cristóbal I, Madoz-Gúrpide J, Manso R, Rojo F, García-Foncillas J. MiR-29c downregulation contributes to metastatic progression in colorectal cancer. Ann Oncol 2015; 26:2199-200. [DOI: 10.1093/annonc/mdv302] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
|
31
|
Santonja C, Soto C, Manso R, Requena L, Piris MA, Rodríguez-Pinilla SM. Primary cutaneous follicular helper T-cell lymphoma. J Cutan Pathol 2015; 43:164-70. [DOI: 10.1111/cup.12614] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Revised: 08/13/2015] [Accepted: 08/16/2015] [Indexed: 11/27/2022]
Affiliation(s)
| | - Carlos Soto
- Hematology Department; Fundación Jiménez Díaz; Madrid Spain
| | - Rebeca Manso
- Pathology Department; Fundación Jiménez Díaz; Madrid Spain
| | - Luis Requena
- Dermatology Department; Fundación Jiménez Díaz; Madrid Spain
| | - Miguel Angel Piris
- Pathology Department; Hospital Universitario Marqués de Valdecilla; Santander Spain
| | | |
Collapse
|
32
|
Cristóbal I, Manso R, González-Alonso P, Rojo F, García-Foncillas J. Should we also evaluate SET together with CIP2A for the treatment with second-generation tyrosine kinase inhibitors in chronic myeloid leukemia? Leukemia 2015; 29:2117. [PMID: 26283451 DOI: 10.1038/leu.2015.201] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- I Cristóbal
- Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Diaz, UAM, University Hospital 'Fundación Jiménez Diaz', Madrid, Spain
| | - R Manso
- Pathology Department, IIS-Fundación Jiménez Diaz, Madrid, Spain
| | | | - F Rojo
- Pathology Department, IIS-Fundación Jiménez Diaz, Madrid, Spain
| | - J García-Foncillas
- Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Diaz, UAM, University Hospital 'Fundación Jiménez Diaz', Madrid, Spain
| |
Collapse
|
33
|
González-Alonso P, Cristóbal I, Manso R, Madoz-Gúrpide J, García-Foncillas J, Rojo F. PP2A inhibition as a novel therapeutic target in castration-resistant prostate cancer. Tumour Biol 2015; 36:5753-5. [DOI: 10.1007/s13277-015-3849-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Accepted: 07/24/2015] [Indexed: 12/18/2022] Open
|
34
|
Cristóbal I, Manso R, González-Alonso P, Madoz-Gurpide J, Rojo F, García-Foncillas J. Clinical Usefulness of 5-FU Metabolic Enzymes as Predictive Markers of Response to Chemotherapy in Colorectal Cancer. World J Surg 2015; 40:1017-8. [PMID: 26228063 DOI: 10.1007/s00268-015-3176-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Ion Cristóbal
- Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", Avda. Reyes Católicos-2, 28040, Madrid, Spain.
| | - Rebeca Manso
- Pathology Department, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", 28040, Madrid, Spain
| | - Paula González-Alonso
- Pathology Department, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", 28040, Madrid, Spain
| | - Juan Madoz-Gurpide
- Pathology Department, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", 28040, Madrid, Spain
| | - Federico Rojo
- Pathology Department, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", 28040, Madrid, Spain
| | - Jesús García-Foncillas
- Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", Avda. Reyes Católicos-2, 28040, Madrid, Spain.
| |
Collapse
|
35
|
Cristóbal I, González-Alonso P, Daoud L, Solano E, Torrejón B, Manso R, Madoz-Gúrpide J, Rojo F, García-Foncillas J. Activation of the Tumor Suppressor PP2A Emerges as a Potential Therapeutic Strategy for Treating Prostate Cancer. Mar Drugs 2015; 13:3276-86. [PMID: 26023836 PMCID: PMC4483628 DOI: 10.3390/md13063276] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2015] [Accepted: 05/13/2015] [Indexed: 12/29/2022] Open
Abstract
Protein phosphatase 2A (PP2A) is a tumor suppressor complex that has recently been reported as a novel and highly relevant molecular target in prostate cancer (PCa). However, its potential therapeutic value remains to be fully clarified. We treated PC-3 and LNCaP cell lines with the PP2A activators forskolin and FTY720 alone or combined with the PP2A inhibitor okadaic acid. We examined PP2A activity, cell growth, prostasphere formation, levels of PP2A phosphorylation, CIP2A and SET expression, and AKT and ERK activation. Interestingly, both forskolin and FTY720 dephosphorylated and activated PP2A, impairing proliferation and prostasphere formation and inducing changes in AKT and ERK phosphorylation. Moreover, FTY720 led to reduced CIP2A levels. Treatment with okadaic acid impaired PP2A activation thus demonstrating the antitumoral PP2A-dependent mechanism of action of both forskolin and FTY720. Levels of PP2A phosphorylation together with SET and CIP2A protein expression were studied in 24 PCa patients and both were associated with high Gleason scores and presence of metastatic disease. Altogether, our results suggest that PP2A inhibition could be involved in PCa progression, and the use of PP2A-activating drugs might represent a novel alternative therapeutic strategy for treating PCa patients.
Collapse
Affiliation(s)
- Ion Cristóbal
- Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital “Fundacion Jimenez Diaz”, E-28040 Madrid, Spain; E-Mail:
- Authors to whom correspondence should be addressed; E-Mails: (I.C.); (F.R.); (J.G.-F.); Tel.: +34-915504800 (ext. 2824)
| | - Paula González-Alonso
- Group of Cancer Biomarkers, Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, E-28040 Madrid, Spain; E-Mails: (P.G.-A.); (L.D.); (E.S.); (R.M.); (J.M.-G.)
| | - Lina Daoud
- Group of Cancer Biomarkers, Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, E-28040 Madrid, Spain; E-Mails: (P.G.-A.); (L.D.); (E.S.); (R.M.); (J.M.-G.)
| | - Esther Solano
- Group of Cancer Biomarkers, Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, E-28040 Madrid, Spain; E-Mails: (P.G.-A.); (L.D.); (E.S.); (R.M.); (J.M.-G.)
| | - Blanca Torrejón
- Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital “Fundacion Jimenez Diaz”, E-28040 Madrid, Spain; E-Mail:
| | - Rebeca Manso
- Group of Cancer Biomarkers, Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, E-28040 Madrid, Spain; E-Mails: (P.G.-A.); (L.D.); (E.S.); (R.M.); (J.M.-G.)
| | - Juan Madoz-Gúrpide
- Group of Cancer Biomarkers, Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, E-28040 Madrid, Spain; E-Mails: (P.G.-A.); (L.D.); (E.S.); (R.M.); (J.M.-G.)
| | - Federico Rojo
- Group of Cancer Biomarkers, Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, E-28040 Madrid, Spain; E-Mails: (P.G.-A.); (L.D.); (E.S.); (R.M.); (J.M.-G.)
- Authors to whom correspondence should be addressed; E-Mails: (I.C.); (F.R.); (J.G.-F.); Tel.: +34-915504800 (ext. 2824)
| | - Jesús García-Foncillas
- Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital “Fundacion Jimenez Diaz”, E-28040 Madrid, Spain; E-Mail:
- Authors to whom correspondence should be addressed; E-Mails: (I.C.); (F.R.); (J.G.-F.); Tel.: +34-915504800 (ext. 2824)
| |
Collapse
|
36
|
Cristóbal I, Rincón R, Manso R, Caramés C, Zazo S, Madoz-Gúrpide J, Rojo F, García-Foncillas J. Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer. Clin Cancer Res 2014; 21:347-56. [PMID: 25388166 DOI: 10.1158/1078-0432.ccr-14-0724] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE SET is an endogenous PP2A inhibitor that might represent a novel molecular target for antitumor therapy. The aim of this study was to evaluate the molecular effects of SET deregulation and its potential clinical significance in metastatic colorectal cancer (mCRC). EXPERIMENTAL DESIGN We studied the biologic effects of SET on cell growth, colonosphere formation, caspase activity, PP2A activation status, and sensitivity to oxaliplatin and FTY720 treatments. Moreover, we analyzed SET expression by immunostaining in 242 patients with mCRC. RESULTS SET deregulation promotes cell growth and colonosphere formation and inhibits PP2A, thereby impairing its antitumor effects. Moreover, SET reduces sensitivity to oxaliplatin in colorectal cancer cell lines, which is restored after FTY720 treatment. SET overexpression was detected in 24.8% (60 of 242) of patients with mCRC and determined significantly shorter overall (8.6 vs. 27 months; P < 0.001) and progression-free survival (7.1 vs. 13.7 months; P < 0.001), and poor response to oxaliplatin-based chemotherapy (P = 0.004). Interestingly, its prognostic value was particularly evident in patients younger than 70 years and in those harboring KRAS mutations. CONCLUSIONS SET overexpression is a frequent event in mCRC that plays a potential oncogenic role associated with worse outcome and resistance to oxaliplatin. Moreover, this alteration defines a subgroup of patients who could benefit from therapies containing PP2A activators such as FTY720.
Collapse
Affiliation(s)
- Ion Cristóbal
- Translational Oncology Division, Oncohealth institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital "Fundacion Jimenez Diaz," Madrid, Spain
| | - Raúl Rincón
- Translational Oncology Division, Oncohealth institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital "Fundacion Jimenez Diaz," Madrid, Spain
| | - Rebeca Manso
- Pathology Department, IIS "Fundación Jiménez Diaz," UAM, Madrid, Spain
| | - Cristina Caramés
- Translational Oncology Division, Oncohealth institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital "Fundacion Jimenez Diaz," Madrid, Spain
| | - Sandra Zazo
- Pathology Department, IIS "Fundación Jiménez Diaz," UAM, Madrid, Spain
| | | | - Federico Rojo
- Pathology Department, IIS "Fundación Jiménez Diaz," UAM, Madrid, Spain.
| | - Jesús García-Foncillas
- Translational Oncology Division, Oncohealth institute, IIS-Fundacion Jimenez Diaz, UAM, University Hospital "Fundacion Jimenez Diaz," Madrid, Spain.
| |
Collapse
|
37
|
Manso R, Rodríguez-Pinilla SM, González-Rincón J, Gómez S, Monsalvo S, Llamas P, Rojo F, Pérez-Callejo D, Cereceda L, Limeres MA, Maeso C, Ferrando L, Pérez-Seoane C, Rodríguez G, Arrinda JM, García-Bragado F, Franco R, Rodriguez-Peralto JL, González-Carreró J, Martín-Dávila F, Piris MA, Sánchez-Beato M. Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas. Haematologica 2014; 100:e25-7. [PMID: 25304611 DOI: 10.3324/haematol.2014.113696] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- Rebeca Manso
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | | | - Julia González-Rincón
- Group of Research in Lymphoma, (Medical Oncology Service), Oncohematology Area, IIS Puerta de Hierro-Majadahonda (IDIPHIM), Madrid, Spain
| | - Sagrario Gómez
- Group of Research in Lymphoma, (Medical Oncology Service), Oncohematology Area, IIS Puerta de Hierro-Majadahonda (IDIPHIM), Madrid, Spain
| | - Silvia Monsalvo
- Haematology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Pilar Llamas
- Haematology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Federico Rojo
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - David Pérez-Callejo
- Group of Research in Lymphoma, (Medical Oncology Service), Oncohematology Area, IIS Puerta de Hierro-Majadahonda (IDIPHIM), Madrid, Spain
| | - Laura Cereceda
- Pathology Department, Hospital U. Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - Miguel A Limeres
- Pathology Department, Hospital U. Canarias Dr. Negrín, Gran Canaria, Canarias, Spain
| | - Carmen Maeso
- Pathology Department, CMI Nuestra Señora de la Candelaria, Sta. Cruz de Tenerife, Spain
| | - Lucía Ferrando
- Pathology Department, Hospital San Pedro de Alcántara, Cáceres, Spain
| | | | | | - José M Arrinda
- Pathology Department, Hospital del Bidasoa, Guipúzcoa, Spain
| | | | - Renato Franco
- Pathology Department, Istituto Nazionale Tumori IRCSS - Fondazione Pascal, Napoli, Italy
| | | | | | | | - Miguel A Piris
- Pathology Department, Hospital U. Marqués de Valdecilla, IDIVAL, Santander, Spain
| | - Margarita Sánchez-Beato
- Group of Research in Lymphoma, (Medical Oncology Service), Oncohematology Area, IIS Puerta de Hierro-Majadahonda (IDIPHIM), Madrid, Spain
| |
Collapse
|
38
|
Cristóbal I, Rincón R, Manso R, Rojo F, García-Foncillas J. Re: Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling. J Natl Cancer Inst 2014; 106:dju196. [PMID: 25136032 DOI: 10.1093/jnci/dju196] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Ion Cristóbal
- : Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAM (IC, RR, JGF) and Pathology Department (RM, FR), University Hospital "Fundacion Jimenez Diaz," Autonomous University of Madrid, Madrid, Spain.
| | - Raúl Rincón
- : Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAM (IC, RR, JGF) and Pathology Department (RM, FR), University Hospital "Fundacion Jimenez Diaz," Autonomous University of Madrid, Madrid, Spain
| | - Rebeca Manso
- : Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAM (IC, RR, JGF) and Pathology Department (RM, FR), University Hospital "Fundacion Jimenez Diaz," Autonomous University of Madrid, Madrid, Spain
| | - Federico Rojo
- : Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAM (IC, RR, JGF) and Pathology Department (RM, FR), University Hospital "Fundacion Jimenez Diaz," Autonomous University of Madrid, Madrid, Spain
| | - Jesús García-Foncillas
- : Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz, UAM (IC, RR, JGF) and Pathology Department (RM, FR), University Hospital "Fundacion Jimenez Diaz," Autonomous University of Madrid, Madrid, Spain.
| |
Collapse
|
39
|
Cristóbal I, Rincón R, Manso R, Madoz-Gúrpide J, Caramés C, del Puerto-Nevado L, Rojo F, García-Foncillas J. Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolin-induced dephosphorylation and activation. Biochim Biophys Acta Mol Basis Dis 2014; 1842:1823-9. [PMID: 24997451 DOI: 10.1016/j.bbadis.2014.06.032] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2014] [Revised: 06/25/2014] [Accepted: 06/26/2014] [Indexed: 12/25/2022]
Abstract
BACKGROUND The tumor suppressor protein phosphatase 2A (PP2A) is frequently inactivated in human cancer and phosphorylation of its catalytic subunit (p-PP2A-C) at tyrosine-307 (Y307) has been described to inhibit this phosphatase. However, its molecular and clinical relevance in colorectal cancer (CRC) remains unclear. METHODS p-PP2A-C Y307 was determined by immunoblotting in 7 CRC cell lines and 35 CRC patients. CRC cells were treated with the PP2A activator forskolin alone or combined with the PP2A inhibitor okadaic acid, 5-fluorouracil and oxaliplatin. We examined cell growth, colonosphere formation, caspase activity and AKT and ERK activation. RESULTS PP2A-C was found hyperphosphorylated in CRC cell lines. Forskolin dephosphorylated and activated PP2A, impairing proliferation and colonosphere formation, and inducing activation of caspase 3/7 and changes in AKT and ERK phosphorylation. Moreover, forskolin showed additive effects with 5-fluorouracil and oxaliplatin treatments. Analysis of p-PP2A-C Y307 in primary tumors confirmed the presence of this alteration in a subgroup of CRC patients. CONCLUSIONS Our data show that PP2A-C hyperphosphorylation is a frequent event that contributes to PP2A inhibition in CRC. Antitumoral effects of forskolin-mediated PP2A activation suggest that the analysis of p-PP2A-C Y307 status could be used to identify a subgroup of patients who would benefit from treatments based on PP2A activators.
Collapse
Affiliation(s)
- Ion Cristóbal
- Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", Autonomous University of Madrid, E-28040 Madrid, Spain.
| | - Raúl Rincón
- Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", Autonomous University of Madrid, E-28040 Madrid, Spain
| | - Rebeca Manso
- Pathology Department, University Hospital "Fundacion Jimenez Diaz", Autonomous University of Madrid, E-28040 Madrid, Spain
| | - Juan Madoz-Gúrpide
- Pathology Department, University Hospital "Fundacion Jimenez Diaz", Autonomous University of Madrid, E-28040 Madrid, Spain
| | - Cristina Caramés
- Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", Autonomous University of Madrid, E-28040 Madrid, Spain
| | - Laura del Puerto-Nevado
- Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", Autonomous University of Madrid, E-28040 Madrid, Spain
| | - Federico Rojo
- Pathology Department, University Hospital "Fundacion Jimenez Diaz", Autonomous University of Madrid, E-28040 Madrid, Spain
| | - Jesús García-Foncillas
- Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", Autonomous University of Madrid, E-28040 Madrid, Spain.
| |
Collapse
|
40
|
Cristóbal I, Rincón R, Manso R, Caramés C, Aguilera O, Madoz-Gurpide J, Rojo F, García-Foncillas J. Deregulation of miR-200b, miR-200c and miR-429 indicates its potential relevant role in patients with colorectal cancer liver metastasis. J Surg Oncol 2014; 110:484-5. [PMID: 24916918 DOI: 10.1002/jso.23661] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2014] [Accepted: 04/28/2014] [Indexed: 11/07/2022]
Affiliation(s)
- Ion Cristóbal
- Translational Oncology Division, Oncohealth Institute, IIS-Fundacion Jimenez Diaz-UAM, University Hospital "Fundacion Jimenez Diaz", Madrid, Spain
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Cristóbal I, Manso R, Rincón R, Madoz-Gúrpide J, Caramés C, Rojo F, García-Foncillas J. Potential involvement of protein phosphatase 2A in temsirolimus-mediated resensitization to cetuximab in colon cancer cells. J Cancer Res Clin Oncol 2014; 140:1249-50. [DOI: 10.1007/s00432-014-1707-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2014] [Accepted: 05/08/2014] [Indexed: 10/25/2022]
|
42
|
Manso R, Rodríguez-Pinilla SM, Lombardia L, Ruiz de Garibay G, del Mar López M, Requena L, Sánchez L, Sánchez-Beato M, Piris MÁ. An A91V SNP in the perforin gene is frequently found in NK/T-cell lymphomas. PLoS One 2014; 9:e91521. [PMID: 24632576 PMCID: PMC3954696 DOI: 10.1371/journal.pone.0091521] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2013] [Accepted: 02/12/2014] [Indexed: 12/24/2022] Open
Abstract
NK/T-cell lymphoma (NKTCL) is the most frequent EBV-related NK/T-cell disease. Its clinical manifestations overlap with those of familial haemophagocytic lymphohistiocytosis (FHLH). Since PERFORIN (PRF1) mutations are present in FHLH, we analysed its role in a series of 12 nasal and 12 extranasal-NKTCLs. 12.5% of the tumours and 25% of the nasal-origin cases had the well-known g.272C>T(p.Ala91Val) pathogenic SNP, which confers a poor prognosis. Two of these cases had a double-CD4/CD8-positive immunophenotype, although no correlation was found with perforin protein expression. p53 was overexpressed in 20% of the tumoral samples, 80% of which were of extranasal origin, while none showed PRF1 SNVs. These results suggest that nasal and extranasal NKTCLs have different biological backgrounds, although this requires validation.
Collapse
Affiliation(s)
- Rebeca Manso
- Pathology Department, Fundación Jiménez Díaz, Madrid, Spain
| | - Socorro María Rodríguez-Pinilla
- Pathology Department, Fundación Jiménez Díaz, Madrid, Spain
- Molecular Pathology Programme, Lymphoma Group, CNIO, Madrid, Spain
- * E-mail:
| | - Luis Lombardia
- Clinical Research Programme, Molecular Diagnostics Clinical Research Unit, CNIO, Madrid, Spain
| | - Gorka Ruiz de Garibay
- Molecular Pathology Programme, Lymphoma Group, CNIO, Madrid, Spain
- Clinical Immunology Department, Hospital Clínico de San Carlos, Madrid, Spain
| | - Maria del Mar López
- Molecular Pathology Programme, Lymphoma Group, CNIO, Madrid, Spain
- Biotechnology Programme, Monoclonal Antibodies Unit, CNIO, Madrid, Spain
| | - Luis Requena
- Dermatology Department, Fundación Jimenez Díaz, Madrid, Spain
| | - Lydia Sánchez
- Biotechnology Programme, Immunohistochemistry Unit, CNIO, Madrid, Spain
| | - Margarita Sánchez-Beato
- Molecular Pathology Programme, Lymphoma Group, CNIO, Madrid, Spain
- Oncology-Haematology Area, Instituto Investigación Sanitaria, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
| | - Miguel Ángel Piris
- Molecular Pathology Programme, Lymphoma Group, CNIO, Madrid, Spain
- Pathology Department, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, IFIMAV, Santander, Spain
| |
Collapse
|
43
|
Cristóbal I, Manso R, Rincón R, Caramés C, Senin C, Borrero A, Martínez-Useros J, Rodriguez M, Zazo S, Aguilera O, Madoz-Gúrpide J, Rojo F, García-Foncillas J. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther 2014; 13:938-47. [PMID: 24448818 DOI: 10.1158/1535-7163.mct-13-0150] [Citation(s) in RCA: 100] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Protein phosphatase 2A (PP2A) is a tumor suppressor that regulates many signaling pathways crucial for cell transformation. In fact, decreased activity of PP2A has been reported as a recurrent alteration in many types of cancer. Here, we show that PP2A is frequently inactivated in patients with colorectal cancer, indicating that PP2A represents a potential therapeutic target for this disease. We identified overexpression of the endogenous PP2A inhibitors SET and CIP2A, and downregulation of regulatory PP2A such as PPP2R2A and PPP2R5E, as contributing mechanisms to PP2A inhibition in colorectal cancer. Moreover, we observed that its restoration using FTY720 impairs proliferation and clonogenic potential of colorectal cancer cells, induces caspase-dependent apoptosis, and affects AKT and extracellular signal-regulated kinase-1/2 activation status. Interestingly, treatment with FTY720 showed an additive effect with 5-fluorouracil, SN-38, and oxaliplatin, drugs used in standard chemotherapy in patients with colorectal cancer. These results suggest that PP2A activity is commonly decreased in colorectal cancer cells, and that the use of PP2A activators, such as FTY720, might represent a potential novel therapeutic strategy in colorectal cancer.
Collapse
Affiliation(s)
- Ion Cristóbal
- Authors' Affiliations: Translational Oncology Division, Health Research Institute and Oncology Department, University Hospital "Fundación Jiménez Díaz," Autonomous University of Madrid; Pathology Department, IIS "Fundación Jiménez Díaz," Madrid, Spain; and Medical Oncology Department, University Hospital of Vigo, Vigo, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Zazo S, Caldes T, González NP, Madoz J, Satre J, Manso R, Ferrandez D, Ramos T, Garcia-Foncillas J, Diaz-Rubio E. Differences in Kras and Braf Mutation Prevalence in Metastatic Colorectal Carcinoma Using High-Sensitivity Taqmelt vs Arms-Scorpion Pcr Assays. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33144-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
45
|
Martin-Cordero L, Garcia JJ, Giraldo E, De la Fuente M, Manso R, Ortega E. Influence of exercise on the circulating levels and macrophage production of IL-1β and IFNγ affected by metabolic syndrome: an obese Zucker rat experimental animal model. Eur J Appl Physiol 2009; 107:535-43. [DOI: 10.1007/s00421-009-1140-4] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/16/2009] [Indexed: 12/22/2022]
|
46
|
Morán M, Delgado J, González B, Manso R, Megías A. Responses of rat myocardial antioxidant defences and heat shock protein HSP72 induced by 12 and 24-week treadmill training. ACTA ACUST UNITED AC 2004; 180:157-66. [PMID: 14738474 DOI: 10.1111/j.0001-6772.2003.01244.x] [Citation(s) in RCA: 54] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
AIM The purpose of this study was to determine the effects of both a short (12 weeks) and a long-term (24 weeks) endurance treadmill-training programme on the levels of oxidative stress markers, the activity of the enzymatic antioxidants, and the content of the 72 kDa heat shock protein (HSP72) in rat myocardium. METHODS Thirty male Wistar rats were randomly assigned to exercise trained (n = 16) and sedentary (n = 14) groups. After 12 week of training, eight rats were killed while the remaining eight continued the training programme until 24 week. RESULTS Seven sedentary controls were killed together with each trained group. Levels of thiobarbituric acid-reactive substances (TBARS), protein carbonyls, and total and oxidized glutathione (tGSH and GSSG) in myocardial homogenates were unchanged by training irrespective of the protocol duration. However, an increased content of the oxidative stress biomarkers was detected in hearts from both the 24-week trained rats and their sedentary controls when compared with their corresponding 12-week groups. The antioxidant enzymatic activities total and mitochondrial superoxide dismutase (tSOD and mtSOD, respectively), glutathione peroxidase (GPX) and glutathione reductase (GR), remained unchanged after the 12-week training period whereas a significant increase in tSOD and mtSOD activities (18%, P < 0.05) was observed in heart homogenates of 24-week trained animals as compared with their sedentary controls. HSP72 expression levels were not significantly modified after 12 week of training but a threefold increase was detected after 24 week (P < 0.05). CONCLUSION These results demonstrate that a long-term endurance training (24 weeks) induced discrete increases in antioxidant enzyme activities in rat myocardium and elicited a marked enhancement in HSP72 expression levels. However, a shorter training programme (12 weeks), was not effective in increasing heart antioxidant defences.
Collapse
Affiliation(s)
- M Morán
- Department of Biochemistry and Molecular Biology I, Faculty of Biology, Complutense University, Madrid, Spain
| | | | | | | | | |
Collapse
|
47
|
González B, Negredo P, Hernando R, Manso R. Protein variants of skeletal muscle regulatory myosin light chain isoforms: prevalence in mammals, generation and transitions during muscle remodelling. Pflugers Arch 2002; 443:377-86. [PMID: 11810206 DOI: 10.1007/s004240100702] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2001] [Revised: 07/26/2001] [Accepted: 07/30/2001] [Indexed: 10/27/2022]
Abstract
The regulatory myosin light chains (rMLCs) of mammalian skeletal muscle display protein diversity arising from the existence of different isotypes and protein phosphorylation. Two-dimensional electrophoresis and immunoblotting allowed us to identify three variants of the slow and fast rMLC isoforms (designated LC2s, LC2s1, LC2s2, and LC2f, LC2f1, LC2f2, respectively, from less to more acidic). This study aimed to characterize their prevalence among different species and muscle types, the mechanism(s) of their generation and their transitions during fast-to-slow fibre type switching. In vitro dephosphorylation and back-phosphorylation experiments and mass spectrometric analysis of tryptic digests indicate that: (1) both acidic variants, within each isoform, contain a phosphorylated peptide, (2) all variants of each isoform share identical tryptic peptides, (3) only one phosphopeptide is present per isoform, and (4) the intermediate-acidic variants of both isoforms contain the same peptide in their phosphorylated and non-phosphorylated forms. The data indicate that the triad pattern of variants results from two partially superimposed doublets of phosphorylated/non-phosphorylated pairs. Continuous, low-frequency electrical stimulation of rat extensor digitorum longus muscle changed the relative proportions of variants within each isoform towards those of the soleus. It is suggested that the doublets of phosphorylated/non-phosphorylated pairs are involved in rMLC exchange during sarcomere remodelling.
Collapse
MESH Headings
- Alkaline Phosphatase/metabolism
- Animals
- Electric Stimulation
- Electrophoresis, Gel, Two-Dimensional
- Isomerism
- Male
- Mass Spectrometry
- Mice
- Muscle Contraction/physiology
- Muscle Fibers, Fast-Twitch/chemistry
- Muscle Fibers, Fast-Twitch/metabolism
- Muscle Fibers, Slow-Twitch/chemistry
- Muscle Fibers, Slow-Twitch/metabolism
- Muscle, Skeletal/chemistry
- Muscle, Skeletal/cytology
- Muscle, Skeletal/metabolism
- Myosin Light Chains/analysis
- Myosin Light Chains/chemistry
- Myosin Light Chains/metabolism
- Phosphorylation
- Rabbits
- Rats
- Rats, Wistar
- Sarcomeres/metabolism
Collapse
Affiliation(s)
- B González
- Department of Molecular Biology, Centre of Molecular Biology "Severo Ochoa" (CSIC-Autonomous University of Madrid), E-28049 Madrid, Spain
| | | | | | | |
Collapse
|
48
|
Abstract
Besides their clinical uses, anabolic steroids (AASs) are self-administered by athletes to improve muscle mass and sports performance. The biological basis for their presumed effectiveness at suprapharmacological doses, however, remains uncertain. Since the expression of high levels of some stress proteins (HSPs) has been associated with an increased tolerance to stress and chronic exercise up-regulates HSP72 in skeletal muscle, this investigation was aimed at testing whether the administration of suprapharmacological doses of AASs, either alone or in conjunction with chronic exercise, induced changes in HSP72. Nandrolone decanoate (ND), an estrene derivative, but not stanozolol (ST), a derivative of the androstane series, up-regulated the levels of HSP72 and changed the proportions of various charge variants of the cytosolic HSP70s in sedentary and exercise-trained rats, exclusively in fast-twitch fibres. Since the expression of HSP73-levels in skeletal muscle was dependent on gender but not on muscle type, and that of HSP72-levels was muscle type specific but gender-independent, ND effects on cytosolic HSP70s could not be explained solely by a functional relationship with sex steroids. The reported results indicate that, by up-regulating the expression levels of HSP72 in fast-twitch fibres, nandrolone decanoate could contribute to improving the tolerance of skeletal muscle to high-intensity training.
Collapse
MESH Headings
- Anabolic Agents/administration & dosage
- Anabolic Agents/pharmacology
- Animals
- Cytosol/drug effects
- Cytosol/metabolism
- Female
- HSP72 Heat-Shock Proteins
- Heat-Shock Proteins/chemistry
- Heat-Shock Proteins/metabolism
- Male
- Muscle Fibers, Fast-Twitch/cytology
- Muscle Fibers, Fast-Twitch/drug effects
- Muscle Fibers, Fast-Twitch/metabolism
- Muscle Fibers, Slow-Twitch/cytology
- Muscle Fibers, Slow-Twitch/drug effects
- Muscle Fibers, Slow-Twitch/metabolism
- Muscle, Skeletal/cytology
- Muscle, Skeletal/drug effects
- Muscle, Skeletal/metabolism
- Nandrolone/administration & dosage
- Nandrolone/analogs & derivatives
- Nandrolone/pharmacology
- Nandrolone Decanoate
- Physical Conditioning, Animal/physiology
- Protein Isoforms/chemistry
- Protein Isoforms/metabolism
- Rats
- Rats, Wistar
- Sex Characteristics
- Stanozolol/administration & dosage
- Stanozolol/pharmacology
- Static Electricity
- Up-Regulation/drug effects
- Weight Gain/drug effects
Collapse
Affiliation(s)
- B González
- Departamento de Biología Molecular, Centro de Biología Molecular 'Severo Ochoa' (CSIC-UAM), Universidad Autónoma de Madrid, Canto Blanco, E-28049, Madrid, Spain
| | | | | |
Collapse
|
49
|
Abstract
Skeletal muscle fibres of untrained animals experience a stress response following exercise. This study was aimed at investigating whether chronic exercise modulates stress proteins of 70 kDa (HSP70s) in skeletal muscle. In the soleus muscle of Wistar rats, adherence to an incremental programme of treadmill running (IPTR) of 3 months duration up-regulated the levels of the beta-subunit of the mitochondrial F1-ATPase and those of HSP72, GRP75 and GRP78. Neither beta-F1-ATPase nor sarcoplasmic reticulum Ca2+-ATPase levels changed with training in the extensor digitorum longus (EDL) muscle. However, HSP70s increased during training. In soleus muscle slices of animals sacrificed 3 days after completing the IPTR, HSP72 and GRP75 were synthesized at lower rates than in sedentary animals while the GRP78 synthesis rate increased. Trained, rested animals also experienced a stress response following acute exercise of lower intensity than that of the actual training sessions. The data suggest that up-regulation of HSP70s by chronic exercise depends upon continued physical activity. Furthermore, the inverse correlation between levels and rates of synthesis of HSP72 during rest periods suggests the operation of a feedback regulatory loop aimed at reestablishing the threshold levels characteristic of unstressed fibres.
Collapse
Affiliation(s)
- B González
- Departamento de Biología Molecular, Centro de Biología Molecular Severo Ochoa (CSIC-UAM), Universidad Autónoma de Madrid, Spain
| | | | | |
Collapse
|
50
|
Hernando R, Manso R. Muscle fibre stress in response to exercise: synthesis, accumulation and isoform transitions of 70-kDa heat-shock proteins. Eur J Biochem 1997; 243:460-7. [PMID: 9030773 DOI: 10.1111/j.1432-1033.1997.0460a.x] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Heat-shock or stress proteins (HSPs) are considered to play an essential role in protecting cells from stress and preparing them to survive new environmental challenges. This study investigates the induction kinetics of synthesis and accumulation of 70-kDa stress proteins in the soleus and extensor digitorum longus (EDL) muscles of the rat following exercise, as well as the isoform transitions that take place during the post-exercise period. Relative synthesis rates (referred to constitutively expressed stress protein HSP73) of the 70-kDa heat-shock proteins were greatly enhanced after a single bout of exercise in both muscles. They peaked early in the post-exercise period and returned to resting levels after approximately 5-6 h. The levels of the inducible stress protein HSP72 in the EDL rose only transiently following exercise, while its accumulation in the soleus was more continuous and stable. The amount of HSP73 increased only transiently in both muscle types after exercise. The constitutive expression of the stress protein HSP72 in the soleus muscle was much higher than in the EDL and other tissues, while that of HSP73 was relatively constant among tissues. Rat skeletal muscle HSP72 and HSP73 were made up of at least three isoforms of the same molecular mass and very close isoelectric points, although only one radiolabelled isoform was detected. The relative proportion of the most abundant isoforms of HSP72, isoforms 1 and 2, as well as their ratio (isoform 2/isoform 1), increased during the post-exercise period. Since isoform 2 of HSP72 partially disappeared after incubating soleus muscle extracts of exercised rats with alkaline phosphatase, these data indicate that phosphorylation of HSP72 is an early event in the stress response of skeletal muscle to exercise stress.
Collapse
Affiliation(s)
- R Hernando
- Department of Molecular Biology, Autonomous University of Madrid, Spain
| | | |
Collapse
|